Only old QCOR longs understand what can happen when an orphan therapy is priced correctly and expands its label. Congratulations to all who held.
Why has SVNT's short interest plummeted ? Why did Dr Meeker, CEO of the largest orphan drug co in the world(GENZ), join SVNT's board this year ? Why did Thompson, ex senior mgr at QCOR- join SVNT's board ? Finally, where might SVNT's share price head to after SVNT aligns Krystexxa's price to rare disease levels and expands its label ? $5/sh ? $10/sh ?
SVNT is releasing their Dialysis study results in the coming weeks......If SVNT enters the Dialysis market early next yr, SVNT is a $10 dollar stock. Why? There are about 450,000 US dialysis pts, of which about 36,000 or 8-9% of them have gout. Of those, about ***3,000-4,000 have RCG......***SVNT's market ......Most importantly, SVNT-like QCOR in 2007-is about to align Krystexxa's price to rare disease levels. When QCOR did the above in Aug of 2007, QCOR went from $1/sh to $6/sh by YE of 2007. SVNT IMHO is QCOR in early 2007. Ugly, unloved, under $1/sh and about to generate sufficient revs to make a decent profit. Good luck to all.